PATENT CLAIM ANALYSIS

Application Number: 16117310
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "006500"]

Abstract:
The application relates to an aqueous pharmaceutical formulation for use in the treatment of Type I or Type II Diabetes Mellitus, wherein the treatment reduces the risk of nocturnal hypoglycemia, said formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine.

Claim (Index 2):
The method of  claim 1 , wherein the aqueous pharmaceutical formulation comprises 200 U/ml to 650 U/mL of insulin glargine [equimolar to 200-650 IU human insulin].

Metadata:
- Claim Count in Document: 65.0
- Percentile: 96.0
- Lexical Diversity: 1.46667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14781857', '14965586', '13467707', '15646760', '13467757']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6669591392373753
- 35 USC 102 Novelty (BERT): 0.8403584843652583
- Combined Prediction Score: 0.6842990737501635
- Mean Citation Score: 638.87267
- Max Citation Score: 1110.2181
- Similarity Product: 1099.7872002209904

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test